Brief Report
Volume 15:02, 2025

Journal of Bioengineering & Biomedical Science

ISSN:2155-9538 Open Access

Epigenetic Modifications in Cancer: Diagnostic and Therapeutic Implications

Alexandra Shalaby*

Department of Personalized Medicine and Rare Diseases, University of Medicine and Pharmacy, Cluj-Napoca, Romania

Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide, driven not only by genetic mutations but also by profound epigenetic alterations. Epigenetics the study of heritable changes in gene expression that do not involve changes to the underlying DNA sequence has emerged as a crucial area of cancer research. Key epigenetic modifications, including DNA methylation, histone modification and non-coding RNA regulation, play significant roles in tumor initiation, progression and resistance to therapy. Unlike genetic mutations, epigenetic changes are potentially reversible, making them attractive targets for diagnostic and therapeutic strategies. Recent advances have highlighted the value of epigenetic biomarkers for early cancer detection, prognosis and prediction of treatment response. Additionally, the development of epigenetic drugs, or "epidrugs," offers promising avenues for precision oncology. This review explores the role of epigenetic modifications in cancer, focusing on their diagnostic utility and therapeutic potential. By understanding the epigenetic landscape of tumors, researchers and clinicians can develop more effective and individualized approaches to cancer management [1].

Description

Epigenetic modifications have emerged as pivotal mechanisms in the development and progression of cancer. Unlike genetic mutations that alter the DNA sequence, epigenetic changes modify gene activity without changing the underlying nucleotide code. These modifications include DNA methylation, histone modifications, chromatin remodeling and regulation by non-coding RNAs. Collectively, these changes play a fundamental role in determining cellular identity and maintaining genomic stability. In cancer, epigenetic dysregulation disrupts normal gene expression patterns, silences tumor suppressor genes and activates oncogenes, thereby contributing to uncontrolled proliferation, evasion of apoptosis, angiogenesis, metastasis and resistance to therapy. As such, understanding the intricacies of epigenetic regulation in tumors opens new avenues for early detection, prognostic evaluation and targeted therapy. DNA methylation is one of the well-characterized epigenetic modifications in cancer. It typically occurs at the 5-carbon of cytosine residues within CpG dinucleotide, often found in clusters known as CpG islands, which are frequently located in gene promoter regions. In normal cells, promoter CpG islands are generally unmethylated, allowing for gene transcription, while methylation in gene bodies and repetitive elements helps maintain genomic stability. In cancer, however, two hallmark methylation changes are observed: global hypomethylation and site-specific promoter hypermethylation [2].

***Address for Correspondence:** Alexandra Shalaby, Department of Personalized Medicine and Rare Diseases, University of Medicine and Pharmacy, Cluj-Napoca, Romania, E-mail: shalaby.alex@clug.ro*

Received: 01 April, 2025, Manuscript No. jbbs-25-165620; **Editor Assigned:** 03 April, 2025, PreQC No. P-165620; **Reviewed:** 15 April, 2025, QC No. Q-165620; **Revised:** 22 April, 2025, Manuscript No. R-165620; **Published:** 29 April, 2025, DOI: 10.37421/2155-9538.2025.15.465

Global DNA hypomethylation can activate proto-oncogenes and contribute to chromosomal instability, while hyper methylation of CpG islands in promoters of tumor suppressor genes leads to their transcriptional silencing. Genes involved in critical processes such as cell cycle regulation DNA repair apoptosis and cell adhesion are frequently silenced by promoter methylation in various cancers. These methylation signatures are not only consistent across patients with the same tumor type but are also detectable in circulating tumor DNA, rendering them attractive biomarkers for early cancer diagnosis and disease monitoring. Histone modifications represent another layer of epigenetic regulation, involving post-translational alterations of histone proteins that impact chromatin structure and gene expression. These modifications include acetylation, methylation, phosphorylation, ubiquitination and sumoylation. The functional outcome of a specific modification depends on the histone residue affected and the type of chemical group added. For example, histone acetylation, catalyzed by Histone Acetyltransferases (HATs), generally leads to an open chromatin conformation and active transcription, while histone deacetylation by Histone Deacetylases (HDACs) condenses chromatin and represses gene expression. Similarly, histone methylation can either activate or repress transcription, depending on the specific lysine or arginine residue modified. In cancer, the balance of histone-modifying enzymes is often disrupted, leading to aberrant expression of oncogenes and silencing of tumor suppressor genes. Non-coding RNAs, particularly MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) have also emerged as key epigenetic regulators in cancer. miRNAs are short, approximately 22-nucleotide RNAs that bind to complementary sequences in messenger RNAs (mRNAs), leading to mRNA degradation or translational repression [3].

The clinical implications of epigenetic alterations in cancer are profound. Because epigenetic changes are reversible, they provide a compelling rationale for the development of epigenetic therapies. DNA methyltransferase inhibitors (DNMTis) such as 5-azacytidine and decitabine were among the first epigenetic drugs approved for clinical use and are currently used in the treatment of myelodysplastic syndromes and acute myeloid leukemia. These agents incorporate into DNA and trap DNA methyltransferases, leading to passive demethylation and reactivation of silenced genes. Histone Deacetylase Inhibitors (HDACis) such as vorinostat and romidepsin are approved for cutaneous T-cell lymphoma and work by restoring acetylation and activating gene expression programs that suppress tumor growth and promote apoptosis. Despite their success in hematological malignancies, the efficacy of these drugs in solid tumors has been limited, likely due to tumor heterogeneity, lack of biomarkers for patient stratification and challenges in drug delivery. However, combination therapies involving epidrugs and conventional chemotherapies, immunotherapies, or targeted agents are being actively investigated in clinical trials, with promising preliminary results. Furthermore, epigenetic biomarkers are increasingly being integrated into precision oncology frameworks. Methylation-based diagnostic assays, such as the Epi proColon test for colorectal cancer and the FDA-approved methylation analysis of the MGMT gene promoter in glioblastoma, exemplify the utility of epigenetics in clinical decision-making [4].

These assays offer several advantages, including high specificity, early detection capabilities and the potential for non-invasive sampling. Moreover, methylation signatures have been employed to classify tumor subtypes more

accurately, predict therapeutic response and monitor minimal residual disease. Technologies such as bisulfite sequencing, ChIP-seq, ATAC-seq and RNA-seq have enabled comprehensive mapping of DNA methylation, histone modifications, chromatin accessibility and transcriptomes at unprecedented resolution. These tools have uncovered previously unrecognized epigenetic drivers of cancer and revealed the extent of intratumoral epigenetic heterogeneity. Such insights are critical for identifying new therapeutic targets and developing combination strategies that address tumor plasticity and drug resistance. Despite these promising developments, several challenges remain in translating epigenetic knowledge into clinical practice. Moreover, current epigenetic drugs often have broad and non-specific effects, leading to unintended consequences and off-target toxicity. To overcome these limitations, efforts are underway to develop next-generation epidrugs that target specific chromatin regulators or readers and to employ delivery systems that enhance tissue specificity and reduce systemic exposure. Additionally, artificial intelligence and machine learning are being leveraged to integrate multi-osmic data and identify epigenetic patterns predictive of treatment response or disease progression [5].

Conclusion

In conclusion, epigenetic modifications constitute a critical dimension of cancer biology, influencing virtually all aspects of tumor behavior. The reversibility of these alterations offers a unique opportunity for therapeutic intervention and precision diagnostics. Continued research into the mechanisms and consequences of epigenetic dysregulation will not only enhance our understanding of cancer pathogenesis but also pave the way for more effective and individualized approaches to cancer prevention, detection and treatment.

Acknowledgment

None.

Conflict of Interest

None.

References

1. Rubin, Joshua B., Joseph S. Lagas, Lauren Broestl and Jasmin Sponagel, et al. "Sex differences in cancer mechanisms." *Biol Sex Differ* 11 (2020): 1-29.

2. Loaeza-Loaeza, Jaqueline, Adriana S. Beltran and Daniel Hernandez-Sotelo. "DNMTs and impact of CpG content, transcription factors, consensus motifs, lncRNAs and histone marks on DNA methylation." *Genes* 11 (2020): 1336.

3. Castaneda, Maria, Petra den Hollander, Nick A. Kuburich and Jeffrey M. Rosen, et al. "Mechanisms of cancer metastasis." *Semin Cancer Bio* 87 (2022): 17-31.

4. Neganova, Margarita E., Sergey G. Klochkov, Yulia R. Aleksandrova and Gjumrakch Aliev. "Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress." *Semin Cancer Bio* 87 (2022): 452–471.

5. Han, Connie C. Cortez, Xiaojing Yang, Peter W. Nichols and Peter A. Jones, et al. "DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter." *Hum Mol Genet* 20 (2011): 4299-4310.

How to cite this article: Shalaby, Alexandra. “Epigenetic Modifications in Cancer: Diagnostic and Therapeutic Implications.” *J Bioengineer & Biomedical Sci* 15 (2025): 465.